Develops drugs for pancreatic cancer with KRAS mutations.
Jun 2026Revenue $154K/yrExpenses $14.3M/yr
No trend
Figures by year
When will Silexion Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $154K and expenses $14.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $155K | $11.8M | −$11.6M |
| Dec 2024 | $28.0K | $12.6M | −$12.6M |
| Dec 2023 | $153K | $4.83M | −$4.68M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.